MX2019014397A - Polipeptidos que enlazan adamts5, mmp13 y agrecano. - Google Patents
Polipeptidos que enlazan adamts5, mmp13 y agrecano.Info
- Publication number
- MX2019014397A MX2019014397A MX2019014397A MX2019014397A MX2019014397A MX 2019014397 A MX2019014397 A MX 2019014397A MX 2019014397 A MX2019014397 A MX 2019014397A MX 2019014397 A MX2019014397 A MX 2019014397A MX 2019014397 A MX2019014397 A MX 2019014397A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- immunoglobulins
- constructs
- mmp13
- aggrecan
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a polipéptidos que enlazan a Agrecano así como ADAMTS5 y/o MMP13, más en particular a polipéptidos que comprenden o consisten esencialmente de inmunoglobulinas que enlazan a Agrecano así como inmunoglobulinas que enlazan a ADAMTS5 y/o inmunoglobulinas que enlazan a MMP13 (también referida en la presente como"polipéptidos de la invención", y "inmunoglobulinas de la invención", respectivamente). La invención también se refiere a constructos que comprenden estas inmunoglobulinas, tal como dominios variables individuales de inmunoglobulina (ISVDs) o polipéptidos así como ácidos nucleicos que codifican estas inmunoglobulinas o polipéptidos (también referido en la presente como "ácidos nucleicos de la invención"; a métodos para preparar estas inmunoglobulinas, polipéptidos y constructos; a las células hospederas que expresan o son capaces de expresar estas inmunoglobulinas o polipéptidos; a composiciones, y en particular a composiciones farmacéuticas, que comprenden estas inmunoglobulinas, polipéptidos, constructos, ácidos nucleicos y/o células hospederas; y a usos de inmunoglobulinas, polipéptidos, constructos, ácidos nucleicos, células hospederas y/o composiciones, en particular para propósitos profilácticos y/o terapéuticos, tal como los propósitos profilácticos y/o terapéuticos mencionados en la presente. Otros aspectos, modalidades, ventajas y aplicaciones de la invención serán claras a partir de la descripción adicional en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17174404 | 2017-06-02 | ||
PCT/EP2018/064668 WO2018220236A1 (en) | 2017-06-02 | 2018-06-04 | Polypeptides binding adamts5, mmp13 and aggrecan |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019014397A true MX2019014397A (es) | 2020-02-10 |
Family
ID=59014503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014397A MX2019014397A (es) | 2017-06-02 | 2018-06-04 | Polipeptidos que enlazan adamts5, mmp13 y agrecano. |
Country Status (12)
Country | Link |
---|---|
US (1) | US11813307B2 (es) |
EP (1) | EP3630817A1 (es) |
JP (1) | JP7249961B2 (es) |
KR (1) | KR20200015912A (es) |
CN (1) | CN110997717A (es) |
AU (1) | AU2018277102A1 (es) |
BR (1) | BR112019025147A2 (es) |
CA (1) | CA3064318A1 (es) |
IL (1) | IL270951A (es) |
MX (1) | MX2019014397A (es) |
TW (1) | TWI826376B (es) |
WO (1) | WO2018220236A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202323287A (zh) | 2016-11-28 | 2023-06-16 | 日商中外製藥股份有限公司 | 包含抗原結合域與運送部分的多胜肽 |
AU2018277343A1 (en) | 2017-06-02 | 2020-01-02 | Ablynx N.V. | Adamts binding immunoglobulins |
WO2024054922A1 (en) * | 2022-09-07 | 2024-03-14 | Synoa Therapeutics, Llc | Methods and compositions comprising novel bispecific antibodies |
Family Cites Families (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB335768A (en) | 1929-10-24 | 1930-10-02 | Jacoviac Maurice | Improvements in protecting devices for gramophone disc records |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
CA2162878A1 (en) | 1993-06-09 | 1994-12-22 | Leon Gerardus Joseph Frenken | Process for producing fusion proteins comprising scfv fragments by a transformed mould |
FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
WO1997049805A2 (en) | 1996-06-27 | 1997-12-31 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
WO1998029560A1 (fr) | 1996-12-26 | 1998-07-09 | Fuji Yakuhin Kogyo Kabushiki Kaisha | Anticorps monoclonal contre la collagenase 3 et procede de dosage immunologique utilisant cet anticorps |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
WO1999037681A2 (en) | 1998-01-26 | 1999-07-29 | Unilever Plc | Method for producing antibody fragments |
AU3295299A (en) | 1998-02-19 | 1999-09-06 | Xcyte Therapies, Inc. | Compositions and methods for regulating lymphocyte activation |
EP0967284A1 (en) | 1998-05-28 | 1999-12-29 | Pfizer Limited | Phosphodiesterases |
EP1141711A1 (en) | 1999-01-05 | 2001-10-10 | Unilever Plc | Binding of antibody fragments to solid supports |
DE60013767T3 (de) | 1999-01-19 | 2009-07-09 | Unilever N.V. | Verfahren zur herstellung von antikörperfragmenten |
AU779162B2 (en) | 1999-02-05 | 2005-01-06 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
CA2367955C (en) | 1999-03-15 | 2009-05-19 | University Of British Columbia | Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
EP1169453A1 (en) | 1999-04-22 | 2002-01-09 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
KR20020012612A (ko) | 1999-06-18 | 2002-02-16 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Atp 결합 카세트 트랜스포터 단백질 abc1을사용하여 콜레스테롤 유출을 증가시키고 hdl을상승시키기 위한 조성물 및 방법 |
WO2001009300A2 (en) | 1999-08-02 | 2001-02-08 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
DE60042789D1 (de) | 1999-11-29 | 2009-10-01 | Bac Ip B V | Immobilisierte antigenbindende moleküle aus einer domäne |
ATE342922T1 (de) | 1999-11-29 | 2006-11-15 | Unilever Nv | Immobilisierung von proteinen mit hilfe eines polypeptidsegments |
WO2001045746A2 (en) | 1999-12-24 | 2001-06-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
ATE428733T1 (de) | 2000-03-14 | 2009-05-15 | Unilever Nv | Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen |
CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
US20040053340A1 (en) | 2000-12-13 | 2004-03-18 | De Haard Johannes Joseph | Protein arrays |
US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
ATE477280T1 (de) | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
US20050037358A1 (en) | 2001-12-21 | 2005-02-17 | Serge Muyldermans | Method for cloning of variable domain sequences |
EP1461085A2 (en) | 2002-01-03 | 2004-09-29 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Immunoconjugates useful for treatment of tumours |
BRPI0315666B8 (pt) | 2002-10-23 | 2021-05-25 | Ludwig Inst For Cancer Res Ltd | dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos |
AU2003286002B2 (en) | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
EP2390268B1 (en) | 2002-11-08 | 2017-11-01 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
RU2455312C2 (ru) | 2002-11-08 | 2012-07-10 | Аблинкс Н.В. | Однодоменные антитела, направленные против фактора некроза опухолей альфа, и их применение |
DE60329627D1 (de) | 2002-12-31 | 2009-11-19 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
EP2390270A1 (en) | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
US7461263B2 (en) | 2003-01-23 | 2008-12-02 | Unspam, Llc. | Method and apparatus for a non-revealing do-not-contact list system |
ATE414106T1 (de) | 2003-06-30 | 2008-11-15 | Domantis Ltd | Pegylierte single-domain-antikörper (dab) |
WO2005018629A1 (en) | 2003-08-12 | 2005-03-03 | Yarbrough William M | Treatment for acne vulgaris and method of use |
PT1687338E (pt) | 2003-11-07 | 2011-01-20 | Ablynx Nv | Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações |
AU2003304638A1 (en) | 2003-12-04 | 2005-07-14 | Wyeth | Biaryl sulfonamides and methods for using same |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
EP1844073A1 (en) | 2005-01-31 | 2007-10-17 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
MX2007014564A (es) | 2005-05-20 | 2008-02-07 | Ablynx Nv | Anticuerpos de vhh de dominio unico contra el factor de von willebrand. |
CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
EP2102244A2 (en) * | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
EP2121757A2 (en) | 2007-02-21 | 2009-11-25 | Ablynx N.V. | Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization |
ES2663512T3 (es) | 2007-05-24 | 2018-04-13 | Ablynx N.V. | Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos |
EP2186894A4 (en) * | 2007-07-10 | 2010-10-20 | Shionogi & Co | MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST MMP13 |
US20090202474A1 (en) * | 2007-11-19 | 2009-08-13 | Wyeth | Expression of orphan gpr64 in inflammatory diseases |
CA2721202A1 (en) | 2008-04-17 | 2009-10-22 | Hilde Adi Pierrette Revets | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
AU2010233658B2 (en) | 2009-04-10 | 2013-11-28 | Ablynx Nv | Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders |
UY32752A (es) * | 2009-07-02 | 2011-01-31 | Glaxo Group Ltd | Polipéptidos y Métodos de Tratamiento |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
KR20220114104A (ko) | 2011-06-23 | 2022-08-17 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
FR2982283B1 (fr) | 2011-11-07 | 2015-01-16 | Faurecia Automotive Ind | Procede de fabrication d'un voile continu de fibres comprenant des fibres longues naturelles, installation et voile associes |
WO2013109829A1 (en) * | 2012-01-20 | 2013-07-25 | Glaxosmithkline Intellectual Property Development Ltd | Anti-adamts4 antibodies and methods of treatment |
FR2996003B1 (fr) | 2012-09-25 | 2014-10-17 | Commissariat Energie Atomique | Methode pour detecter specifiquement dans un echantillon une metalloprotease matricielle (mmp) d'interet uniquement dans sa forme active |
WO2015056808A1 (en) * | 2013-10-15 | 2015-04-23 | Genefrontier Corporation | Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases |
KR20150115106A (ko) * | 2014-04-02 | 2015-10-14 | 광주과학기술원 | Zinc-ZIP8-MTF1 억제제를 유효성분으로 포함하는 관절질환 예방 또는 치료용 약제학적 조성물 |
EP3974449A1 (en) | 2015-11-13 | 2022-03-30 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
GB201617622D0 (en) | 2016-10-18 | 2016-11-30 | VIB VZW and Universiteit Gent | Means and methods to treat inflammation |
-
2018
- 2018-06-04 CA CA3064318A patent/CA3064318A1/en active Pending
- 2018-06-04 AU AU2018277102A patent/AU2018277102A1/en active Pending
- 2018-06-04 WO PCT/EP2018/064668 patent/WO2018220236A1/en active Application Filing
- 2018-06-04 JP JP2019566730A patent/JP7249961B2/ja active Active
- 2018-06-04 CN CN201880049024.2A patent/CN110997717A/zh active Pending
- 2018-06-04 TW TW107119217A patent/TWI826376B/zh active
- 2018-06-04 MX MX2019014397A patent/MX2019014397A/es unknown
- 2018-06-04 US US16/617,846 patent/US11813307B2/en active Active
- 2018-06-04 KR KR1020197038466A patent/KR20200015912A/ko not_active Application Discontinuation
- 2018-06-04 BR BR112019025147-2A patent/BR112019025147A2/pt unknown
- 2018-06-04 EP EP18730691.5A patent/EP3630817A1/en active Pending
-
2019
- 2019-11-26 IL IL270951A patent/IL270951A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP7249961B2 (ja) | 2023-03-31 |
EP3630817A1 (en) | 2020-04-08 |
TW201920291A (zh) | 2019-06-01 |
US11813307B2 (en) | 2023-11-14 |
IL270951A (en) | 2020-01-30 |
JP2020523986A (ja) | 2020-08-13 |
WO2018220236A1 (en) | 2018-12-06 |
AU2018277102A1 (en) | 2019-12-19 |
BR112019025147A2 (pt) | 2020-06-23 |
TWI826376B (zh) | 2023-12-21 |
CA3064318A1 (en) | 2018-12-06 |
US20210008160A1 (en) | 2021-01-14 |
KR20200015912A (ko) | 2020-02-13 |
RU2019143684A (ru) | 2021-07-13 |
CN110997717A (zh) | 2020-04-10 |
RU2019143684A3 (es) | 2021-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
MX2020009394A (es) | Anticuerpos anti-cd73 y métodos de uso de los mismos. | |
PH12020551907A1 (en) | Antagonizing cd73 antibody | |
MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
PH12019500709A1 (en) | Anti-lag-3 antibodies and methods of use thereof | |
SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
WO2017193032A3 (en) | Bispecific binding proteins and uses thereof | |
MX2022004042A (es) | Proteinas de union multiespecificas para tratamiento contra el cancer. | |
WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
MX2017009767A (es) | Nuevas proteínas específicas para la angiogénesis. | |
TN2014000360A1 (en) | Cx3cr1-binding polypeptides | |
MX2019014400A (es) | Inmunoglobulinas que se unen a adamts. | |
PH12018501025A1 (en) | Improved tnf binders | |
MX2019014397A (es) | Polipeptidos que enlazan adamts5, mmp13 y agrecano. | |
MX2022002315A (es) | Anticuerpos anti-cd96 y sus metodos de uso. | |
AU2018277310A1 (en) | Aggrecan binding immunoglobulins | |
WO2016063026A3 (en) | Selective nav protein binders | |
MX2019014448A (es) | Inmunoglobulinas de enlace a mmp13. | |
MX2015014198A (es) | Anticuerpos cuyo objetivo es m-csf. | |
EA202191658A1 (ru) | Антитела против фактора c2b комплемента человека и способы применения | |
MX2020009507A (es) | Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos. | |
WO2016040767A3 (en) | Chrdl-1 epitopes and antibodies | |
TW202417517A (zh) | 與mmp13結合之免疫球蛋白 |